SLNCF

Healthcare Biotechnology

Silence Therapeutics plc

$4.00

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

745.85M

Avg Volume

110

EPS

-$0.43

52W High

$5.99

52W Low

$1.06

Div. Yield

0.0%

Valuation

Forward P/E

-10.51

P/B Ratio

14.74

P/S Ratio

1212.76

EV/EBITDA

-7.74

EV/Revenue

804.91

Margins

Gross Margin 85.9%

Operating Margin (10475.6%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(90.4%)

Return on Assets

(29.6%)

Liquidity & Leverage

Current Ratio

7.42

Quick Ratio

6.40

Debt / Equity

0.00

Total Cash

72.05M

Total Debt

112,000

About

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.